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Abstract
Background: Human papillomavirus type 16 (HPV-16) infection is an important cause of cervical cancer, other anogenital
cancers and, possibly, some oral and pharyngeal cancers. The association of HPV-16 with oesophageal and with prostate
cancers has not been firmly established.
Methods: We analysed sera from 3,757 HIV seronegative black South Africans using an anti-HPV IgG enzyme-linked
immunosorbent assay (ELISA). The subjects were recruited from 1995 to 2000 as part of an ongoing cancer case control
study. Cases were patients with newly diagnosed cancers of the cervix (n = 946), other anogenital organs (n = 80), the oral
cavity and pharynx (n = 102), the oesophagus (n = 369) or the prostate (n = 205). The comparison group consisted of 2,055
age and sex-matched patients randomly selected from the same data base, diagnosed at the same hospitals, but with a
vascular disease or with a cancer unrelated to HPV infection. Subjects' sera were randomly and blindly allocated onto ELISA
plates. Optical density (OD) levels of anti-HPV-16 IgG of > 0.45 and ≥ 0.767 were taken to be cut-offs for negative, medium
and high antibody levels.
Results: After adjustment for potential confounders, cancer types that showed a statistically significant association with
increased anti-HPV-16 IgG antibody (Ab) levels were cancer of the cervix (OR for medium Ab levels = 1.6, and for high =
2.4, p < 0.0001), cancers of other anogenital organs (OR for medium or high Ab levels = 2.5, p = 0.002), and cancer of the
oesophagus (OR for medium Ab = 1.3, and high Ab levels = 1.6 p = 0.002). Cancers of the oral cavity and pharynx showed
a borderline significant association in the unadjusted model (p = 0.05) but after adjustment for confounding the trend in
relation to Ab levels was positive but not statistically significant (OR for medium Ab = 1.1, and high Ab = 1.5 p = 0.13).
Prostate cancer was not associated with HPV-16 seropositivity (OR for medium Ab level = 1.4, and for high Ab level = 1.3,
p = 0.3).
Conclusion: If there is indeed an association between HPV-16 and oesophageal and possibly also some oral cavity and
pharyngeal cancers, then emerging HPV vaccines may also reduce, at least in part, the incidence of these leading cancer
types.
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Background
Cancers of the cervix, oesophagus, oral cavity and prostate
gland are among the leading cancer types in South
Africa[1]. Infection with specific oncogenic human papil-
lomaviruses (HPV) such as HPV-16 is regarded as a neces-
sary cause of cervical and other anogenital cancers [2] and
has also been associated with cancers of the oral cavity
and especially the pharynx [3]. HPV-16 infection has been
linked to squamous cell carcinoma of the oesophagus in
several epidemiological studies and clinical series [4-6],
but not in others [7]. Likewise, prostate cancer has been
associated with certain HPV genotypes in some studies [8-
10], but not in others [11,12].
The aim of this study was to assess, in a standardised man-
ner, the known association between anti-HPV-16 IgG
antibodies and cancers of the cervix and anogenital region
and to explore the possible associations between anti-
HPV-16 IgG serological responses and cancers of the oral
cavity and pharynx, oesophagus and prostate. Measuring
the presence and viral loads of various HPV DNA geno-
types in the target organs would have been the method of
choice, but collecting tissue from cases and controls is not
practical in large-scale epidemiological studies. Thus sero-
logical markers of HPV infection were used.
Materials and methods
Recruitment of cases and controls
An ongoing case-control study on lifestyle factors, infec-
tion and cancer began in 1995 in the main public referral
hospitals for cancer treatment in greater Johannesburg,
South Africa. Infectious agents already tested include HIV
[13], human herpes virus 8[14], and human herpesviruses
1 to 6 [15]. All newly diagnosed black African adults with
cancer are eligible for inclusion. Patients are asked
whether they have previously had a cancer and, where
possible, this is verified by checking records. In about
80% of cases the diagnosis and primary site were con-
firmed by histology, haematology, or cytology [13]. Dur-
ing the time period for this study (1995 – 2000) selected
patients from the same hospitals with a new diagnosis of
cardiovascular disease were also included. Following writ-
ten or witnessed oral informed consent, patients were
interviewed by trained nurses using a two-page demo-
graphic and lifestyle questionnaire[16]. Interviews were
conducted in the main vernacular languages. Blood spec-
imens were collected prior to initiation of treatment. Sera
were separated, aliquotted and stored at minus 30°C.
Sera from subjects were batch tested for HIV-1 by the
South African National Health Laboratory Service Serol-
ogy Laboratory using standard serological methods
described previously [13]. The current analysis used ques-
tionnaire data and serum samples from 3757 HIV seron-
egative subjects in order to determine the relative
importance of HPV-16 in relation to risk of a number of
cancer types. Cases were subjects with cancer of the cervix
(n = 946), other anogenital organs (61 females, 19 males,
comprising 10 anal, 51 vulval, 6 vaginal and 13 penile
cancers), cancers of the oral cavity and pharynx (21
females, 81 males, comprising 20 cancers of the tongue,
25 of the floor of mouth, 8 of the gum, 10 of the parotid/
salivary glands, 6 of the tonsil, and 11 of the oro-naso
pharynx, and 22 cancers in other regions of the oral cav-
ity), cancer of the oesophagus (126 female, 243 males)
and cancer of the prostate (205 males). The comparison
group consisted of 2,055 age and sex-matched patients
randomly selected from the same data base, diagnosed at
the same hospitals, but with a vascular disease or with a
cancer type thought to be unrelated to HPV infection.
These comprised 1382 female and 673 male subjects with
breast cancer (506 females), colorectal cancer (60 females,
51 males), endocrine cancer (19 females, 9 males), Hodg-
kin lymphoma (37 females, 37 males), leukaemia (104
females, 103 males), liver cancer (9 females, 13 males),
lung cancer (34 females, 99 males), myeloma (53
females, 65 males), non-Hodgkin lymphoma (27
females, 40 males), stomach cancer (27 females, 36
males), other minor cancer types (132 females, 127
males) and with cardiovascular disease (374 females, 93
males).
HPV-16 serology
Serum aliquots from all participants were air freighted in
dry ice to the University of Cape Town, Division of Medi-
cal Virology for anti-HPV-16 IgG testing by ELISA. The
ELISA was a modification of that described by Studentsov
and colleagues [17,18], using polymer solutions (Sigma)
for blocking (polyvinyl alcohol, PVA) and secondary anti-
body (polyvinylpyrrolidone, PVP) enhancement. This
enhanced ELISA uses serum at a 1:100 dilution instead of
a previous 1:20 dilution [19]. Plates were coated with 100
µl of 0.05 µg virus-like particles (VLP) to HPV-16, (Med-
Immune Inc) in phosphate buffer solution (PBS) over-
night at 4°C. After washing twice in PBS, plates were
blocked with 200 µl 0.5% PVA in PBS (0.5% PVA) at
room temperature. After washing six times in PBS, serum
diluted 1:100 in 0.5% PVA was added and allowed to
incubate at 37°C for one hour. The subsequent procedure
used 0.8% PVP and 0.5% PVA in PBS for the dilution of
the horse radish peroxidase (HRP) conjugated anti-
human IgG with six PBS washes between this and other
procedures [19].
Minimising laboratory variation
To minimise laboratory variation and case-control bias,
serum aliquots from the cases and the comparison group
were randomly allocated on each ELISA plate by five age
groups (25–34, 35–44, 45–54, 55–64, and 65–74 years)
and by case-comparison status. Specimens from malesInfectious Agents and Cancer 2007, 2:6 http://www.infectagentscancer.com/content/2/1/6
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and females were run on separate plates. The laboratory
staff were 'blinded' with regard to the distribution of the
aliquots on the plates. In addition, for quality control pur-
poses, ten adult consenting volunteer donors provided
anonymous blood samples to use as plate controls. These
donors were tested for anti-HPV-16 IgG antibody
responses prior to the commencement of this study, and
the sera of three donors who were found to have low,
medium and high anti- HPV-16 IgG optical density values
were added on wells on each of the 111 ELISA plates. As a
secondary precaution, pooled sera of children collected
for other purposes were added on wells of each ELISA
plate to represent an additional reference group. Chil-
dren's anti-HPV IgG titres are usually low, and therefore
could represent a true negative (uninfected) group [2].
Intra-class correlation coefficients were estimated in the
volunteer and children's sera to measure the plate-to-plate
assay variability.
Determination of cut-off values for negative, medium and 
high antibody levels
The ELISA optical density (OD) cut-off for positivity was
0.45, determined by calculating the mean plus 4 standard
deviations (SD) of the absorbance values obtained from
children's serum samples tested by VLP-16 IgG ELISA
[20]. OD values between 0.45 and 0.767 were considered
medium antibody levels and OD values greater than
0.767 were considered as high. The value of 0.767 was the
median OD value in the seropositive comparison group.
Due to small numbers, cancers of the male and female
anogenital organs (aside from cervix) were only divided
into HPV-16 IgG seropositives (OD ≥ 0.45) and seroneg-
atives (OD <0.45).
Statistical methods
In the comparison group, bivariate, chi-squared and t-sta-
tistics were calculated to measure the association between
anti-HPV-16 IgG optical density and a number of demo-
graphic and lifestyle factors, in males and females, such as
age (18–34, 35–54 and 55–74 years), years of education
(less than 4, 4 to 6, 7 to 9 and 10 or more years), lifetime
number of sexual partners (0 to 1, 2 to 4, 5 or more), res-
idence (urban/rural), birthplace (urban/rural), alcohol
consumption (ever/never), tobacco smoking (never, ex-,
current), and parity (0 to 2, 3 to 5 and 6 or more children),
all of which were found in some studies to be associated
with HPV acquisition and with the disease conditions of
interest [2]. In the analysis of cancers of male and female
anogenital organs a variable containing sex and parity was
included in the model (males, females with 0–2, with 3–
5 and with 6 or more children). To estimate the preva-
lence of the HPV-16 IgG seropositivity in the cases and the
comparison group (subjects with other cancer types or
with vascular disease), logistic regression was used,
adjusted for age, sex and number of sexual partners, using
females with 0–1 sexual partners, aged 18–34 years as the
reference. The odds and 95% confidence intervals, were
transformed into proportions (seropositivity) by the for-
mula odds/1+odds. The distribution of HIV in relation to
a number of socio-demographic variables in the compari-
son group is shown in table 1.
Odds ratios to compare anti-HPV-16 IgG levels in patients
with each cancer type of interest (cervical, other anogeni-
tal, oral and pharyngeal, oesophageal, and prostate) and
the comparison group were calculated using uncondi-
tional logistic regression and shown in table 2. For each
cancer type of interest, odds ratios were first adjusted for
age and sex and then further adjusted for age group, sex
(only for cancers of the oral cavity and pharynx, oesopha-
gus and other anogenital organs) and also for a number of
additional confounders which were thought to be impor-
tant in the aetiology of cervical (number of sexual part-
ners, smoking, parity and hormonal contraception
[21,22], other anogenital (smoking, parity, number of
sexual partners-in keeping with cervical cancer) oral cavity
and pharynx (smoking, alcohol and number of sexual
partners [3]), oesophageal (smoking, alcohol [13]), and
prostate cancer (number of sexual partners [8-10]). We
adjusted for education (as a proxy of socio-economic con-
dition) and for birthplace and current residence (to take
account for possible geographical differences in cancer
incidence and referral) in all the models. A third, parsimo-
nious model, was obtained by removing variables from
the full model and monitoring the effect on the odds ratio
for HPV infection. Results are summarised in Table 2.
Missing values were included wherever possible as an
additional category for each variable in the models. The
number of cases of prostate cancer aged 18–34 was too
small for proper adjustment using logistic regression so
these were excluded. All p values are 2-tailed.
Results
The anti-HPV-16 IgG levels of pooled children's sera were
indeed low (mean OD = 0.015, SD = 0.012) compared to
the mean antibody level of the (adult) study subjects
(mean OD = 0.825, SD = 0.635). To measure the repro-
ducibility of the ELISA assay between plates, the intra-
class correlation coefficient was calculated for the high,
medium and low anti-HPV IgG levels of the volunteer sera
and was found to be excellent (ρ = 0.9724).
Using an optical density cut-off of 0.45, the HPV-16 IgG
seropositivity in the comparison group was 63% in
females and 58% in males (age adjusted χ2 = 5.34, p =
0.02). In females, there was a significant inverse trend in
the HPV-16 seropositivity in relation to age, being higher
in the youngest age group 18–34 years (67%) and lower
in the older age group (55–74 years, 59%, p trend = 0.004,
Table 1). By contrast, in males, there was an increasedInfectious Agents and Cancer 2007, 2:6 http://www.infectagentscancer.com/content/2/1/6
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seropositivity of anti-HPV-16 IgG in relation to increasing
age, from 42% in those aged 18–34 years to 61% in those
aged 65–74 years (p-trend = 0.003). Age-adjusted anti-
HPV-16 IgG seropositivity was associated with an increas-
ing number of sexual partners in females only, using the
selected groupings (p-trend was 0.01 in females and 0.1 in
males). Anti-HPV-16 IgG seropositivity was unrelated to
level of education, place of birth (urban/rural), alcohol
consumption (ever/never), tobacco smoking, or parity,
age at first child birth, or use of hormonal contraception
(data not shown for the last two variables). HPV-16 sero-
positivity was significantly higher in males resident in
rural (67%), vs. urban areas (57%), (p = 0.05), but this
association was not observed in females.
Anti-HPV-16 IgG seropositivity in the comparison group
was similar in those with vascular disease and those with
the other cancers (Figure 1). Table 2 shows the odds ratios
(OR) and 95% confidence intervals (95%CI) for the can-
cers of interest relative to the comparison group by anti-
HPV-16 IgG antibody levels. An increasing trend in the
risk of developing cancer of the cervix was found in rela-
tion to increasing anti-HPV-16 IgG levels; those with
medium and high levels having adjusted odds ratios (OR)
Table 1: Distribution of anti-HPV-16-IgG seropositivity in the comparison group
Females Males
N % HPV +ve (>0.45) p *,# Mean HPV-16-OD N % HPV +ve (>0.45) P *, # Mean HPV-16 OD
Age (years)
18–34 113 67.3 0.004* 0.73 76 42.1 0.003* 0.53
35–54 679 66.0 0.76 315 57.8 0.63
55–74 590 58.6 0.65 282 61.3 0.63
All ages 1382 63.0 673 57.8 
Years of Education
<4 264 64.8 0.8* 0.71 140 64.3 0.1* 0.70
4–6 224 58.0 0.69 135 56.3 0.62
7–9 529 63.1 0.70 220 60.9 0.63
10 and + 359 64.1 0.73 158 48.7 0.53
Missing 6 - - 20 - -
Number of sexual partners
0–1 261 57.9 0.01* 0.66 57 50.9 0.1* 0.56
2–4 834 63.1 0.69 286 55.6 0.64
5+ 260 68.1 0.82 299 61.2 0.61
Missing 27 - - 31 - -
Current residence
Urban 1154 62.4 0.2# 0.71 557 56.6 0.05# 0.61
Rural 207 67.1 0.72 94 67.0 0.70
Missing 21 - - 22 - -
Place of birth
Urban 735 64.6 0.2# 0.74 318 56.0 0.2# 0.58
Rural 646 61.0 0.68 338 60.4 0.66
Missing 1 - - 17 -
Alcohol consumption
Ever 726 64.7 0.3# 0.73 516 57.6 0.5# 0.61
Never 651 61.1 0.69 139 59.7 0.66
Missing 5 -- - 18 - -
Smoking
Current 92 69.6 0.5* 0.79 218 58.7 0.8* 0.60
Ex- 184 59.8 0.70 260 58.5 0.56
Never 1094 63.0 0.71 179 55.9 0.64
Missing 12 - - 16 - -
Parity
0–2 510 66.9 0.1* 0.77 - - - -
3–5 607 60.3 0.68 - - - -
6+ 254 61.0 0.67 - - - -
Missing 11 - - - - - - -
P-values are either tests for trend* or homogeneity#. P-values for variables other than age are age-adjusted.Infectious Agents and Cancer 2007, 2:6 http://www.infectagentscancer.com/content/2/1/6
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of 1.63 and 2.48 respectively (p trend <0.0001). Males
and females seropositive against HPV-16 IgG antibodies
were also at higher risk of developing cancer of other ano-
genital organs (OR = 2.50, p = 0.003 – the sample size was
too small to divide the subjects with anogenital cancers
into those with medium and high antibody levels). For
cancer of the oral cavity and pharynx, subjects with
medium and high anti-HPV-16 IgG levels had ORs
(adjusted for age and sex) of 1.18 and 1.65, respectively (p
trend = 0.05). However, after adjustment for potential
confounding factors the odds ratios in relation to medium
and high antibody levels were 1.09 and 1.47 respectively,
p trend = 0.13). The risk for cancer of the oesophagus was
found to be associated with increasing anti-HPV-16 IgG
levels; adjusted odds ratios were 1.26 and 1.59 for
medium and high antibody levels respectively (p-trend =
0.002). To test whether there was a differential effect of
HPV -16 seropositivity and oesophageal cancer in males
and females, we added an interaction term of sex by HPV
-16 status into the logistic model; however this was not
statistically significant (p = 0.63).
No statistically significant associations were found
between anti-HPV-16 IgG antibodies and cancer of the
Table 2: Risk of developing selected cancers in relation to anti-HPV-16 IgG OD levels
Cancer site or type HPV-16 OD status Comparison 
group (N)
Cases (N) OR1 (95% CI) Adj. OR2 (95% CI) Adj. OR3 (95% CI)
Cervix (women only)
Low (Negative)<0.45 512 201 1 1 1
Medium 0.45–0.767 411 273 1.71 1.50(1.18–1.90) 1.64(1.30–2.08)
High >0.767 459 472 2.63 2.38 (1.91–2.97) 2.50(2.01–3.11)
P-trend <0.0001 <0.0001* <0.0001†
Anogenital organs 
(men and women)
Low <0.45 798 15 1 1 1
Medium or high > = 0.45 1257 65 2.69 2.30(1.28–4.11) 2.49(1.40–4.43)
P= 0.0007 0.005** 0.002††
Oral cavity and 
pharynx (men and 
women)
Low (Negative)<0.45 798 33 1 1 1
Medium 0.45–0.767 625 32 1.18 1.13(0.66–1.91) 1.09(0.64–1.83)
High >0.767 632 37 1.65 1.49(0.89–2.51) 1.47(0.88–2.47)
P-trend 0.05 0.13*** 0.13†††
Oesophagus (men 
and women)
Low (Negative)<0.45 798 112 1 1 1
Medium 0.45–0.767 625 123 1.33 1.25(0.92–1.69) 1.26(0.94–1.70)
High >0.767 632 134 1.65 1.53(1.14–2.07) 1.59(1.19–2.13)
P-trend 0.0006 0.0005*** 0.002††††
Prostate (men only)
Low (Negative)<0.45 286 65 1 1 1
Medium 0.45–0.767 214 81 1.39 1.33(0.87–2.04) 1.39(0.93–2.09)
High >0.767 173 59 1.33 1.22(0.77–1.93) 1.33(0.86–2.07)
P-trend 0.35**** 0.18†††††
Notes: Adjustment factors
OR1: Age and sex (where appropriate)
OR2:
* Age group, education, parity, number of sexual partners, birthplace, current residence and smoking
** Age group, education, parity and sex (see methods), number of sexual partners, birthplace, current residence and smoking.
*** Age group, sex, education, birthplace, current residence, alcohol usage and smoking.
**** Age group, education, birthplace, current residence and number of sexual partners.
OR3:
† Education, parity, number of sexual partners and smoking
†† Sex, smoking, parity
††† Age group, sex, smoking, current residence, education
†††† Age group, sex, smoking, education
††††† Age group, sex, smoking, educationInfectious Agents and Cancer 2007, 2:6 http://www.infectagentscancer.com/content/2/1/6
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prostate for either medium (adjusted OR = 1.34) or high




This study is part of an ongoing cancer case control study
run in the two major tertiary hospitals in Johannesburg,
where the degree of diagnostic accuracy is high. Controls
(comparison group) were selected from the pool of inci-
dent cancer patients and patients admitted for the fist time
with vascular disease. In this study the controls were
selected by excluding subjects whose cancer type was
thought associated with the exposure of interest, e.g. those
with squamous cell skin cancers and laryngeal cancers. We
also excluded subjects with endometrial and ovarian can-
cer to avoid misclassification of the genital cancers of
interest. Whilst a number of co-factors are thought to be
important in the aetiology of the cancer types of interest
(e.g. smoking), these were not part of the main hypothesis
and so smoking related cancers were retained in the com-
parison group.
HPV-16 serology
Virus-like particles (VLPs) engineered from various HPV
types and used in enzyme-linked immunoassay (ELISA)
have been validated as type specific antigens to detect
serological markers of past and present HPV infection [23]
Studentsov et al[18] indicated a twofold increase in sensi-
tivity and specificity of the serological detection of anti-
HPV-16 IgG antibodies using a polymer enhanced HPV-
16 VLP ELISA protocol compared to previous HPV16 VLP
ELISAs. As well as the improved detection of anti-HPV-16
IgG antibodies, the polymer-based ELISA also detects
cross-reactive responses from closely related types to HPV-
16 of alpha species A9 (containing HPV types HPV -31, -
33, -35, -52 and -58) [24]. Williamson et al [25] found
that in Cape Town, South Africa, the prevalence of HPV
genotypes in cervical cancers was 46% for HPV-16, 2% for
HPV-18, 6% for HPV-31, and 6% for HPV-33. Pegoraro et
al [26] examined cervical tumour tissue from Zulu speak-
ing black women in Durban, South Africa and found prev-
alences of 47% for HPV-16, 14% for HPV-18 and 25% for
other HPV types. In another South African study of
women with cervical or pre-invasive cancer [27], the prev-
Adjusted proportions seropositive for HPV-16 IgG among the cases and comparison group Figure 1
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alence of oncogenic genotypes in cervical biopsies was:
HPV-16: 47%, HPV-18: 14%, HPV-33: 10%, HPV-35: 2%,
HPV-52: 2% and HPV-58: 1%. However, the prevalence of
types other than HPV-16 is expected to be low as
responses to species A9 types other than HPV-16 would be
to minor VLP epitopes [28] and so the antibody response
in this study would be predominantly due to HPV-16.
Viral persistency and high viral loads are associated with
an increase in the risk of cervical and anogenital can-
cers[29-31]. Anti-HPV IgG VLP ELISA optical density
(which is proportional to the amount of antibody
present) was found to be a reliable marker of past expo-
sure to the HPV type tested and an indirect marker of high
HPV viral loads measured using PCR[18].
In this study, a number of measures were introduced to
minimise laboratory variation and bias. These included: i)
using individual sera from a group of local volunteers to
assess the reliability of the assay at low, moderate and
high anti-HPV 16 IgG optical density levels; ii) adding a
group of children's sera as a cross check for negative con-
trol values; iii) randomly allocating cases and the compar-
ison groups on each plate to minimise case control bias;
iv) 'blinding' the laboratory so that the assays were per-
formed without knowledge of the disease or demographic
status of the subjects; and v) testing cancers that are
known to be associated with HPV (cervix, anogenital) and
those with an uncertain association (oral cavity and phar-
ynx, oesophageal, prostate) using the same assay, under
the same laboratory conditions.
Whilst there is no gold standard to evaluate whether the
anti-HPV-16 IgG optical density cut-off levels truly reflect
infection by HPV 16, a cut-off of 4 SD above that found
among healthy children in a previous study (>0.45)
seemed appropriate for the purposes of this study [19].
This is similar to the approach used by Wang et al [32],
who used 5SD as an appropriate cut off point as a proxy
of persistent HPV infection. Using tertiles of anti-HPV IgG
optical density level yielded similar results. Approxi-
mately 60% of the subjects in the comparison group (63%
in females, 58% in males) had values above the cut off
level.
Demographic distribution of anti-HPV16 IgG
In this study, the anti-HPV 16 IgG seropositivity patterns
observed in the comparison group generally concur with
other studies, namely that females have a higher seropos-
itivity or prevalence of anti-HPV 16 IgG (and higher mean
OD levels) than males, despite the latter reporting a
higher number of sexual partners [33,34]. Stone et al [34]
suggested that, in the USA, the sex differences may be due
to differences in immune response, or higher HPV clear-
ance rates among males. Very little work has been done in
Africa on the demographic distribution of HPV in men. In
this study anti-HPV 16 IgG seropositivity was not signifi-
cantly associated with lower educational level; however
there was a significant association with rural residence in
men but not in women. It has been speculated that
women using hormonal contraception might be more
susceptible to HPV infection [35] but we did not observe
this (data available on request) nor did another recent
local study[36], nor was such an association found in the
systematic review by Green and colleagues [35].
HPV-16 in relation to different cancer types
After adjustment for a number of potential confounding
factors, in keeping with other studies, women with
medium and high anti-HPV-16 IgG OD levels showed
increasing risks of developing cancer of the cervix. Simi-
larly, women and men with cancers of other anogenital
organs showed at least a doubling of risk in relation to
anti-HPV-16 IgG positivity. Consistent with a recent
multi-centre study [3], we observed a weak association
between anti-HPV 16 IgG antibody levels and cancer of
the oral cavity and pharynx, but the test for trend ranged
from borderline significance in the initial model, adjusted
for age and sex (p = 0.05) to non-significant (p = 0.13)
when all the important confounding variables were
retained, suggesting that some confounding by lifestyle
may be important. In the multicentre study [3] a stronger
association was found between HPV-16 and oral cavity
and pharyngeal cancers, but the numbers in this study
would be insufficient to draw proper comparisons. Vari-
ous oncogenic HPV types including HPV-16 infect squa-
mous epithelia [2]. Squamous cell cancer is the
predominant oesophageal cancer type found in South
Africa[1]. A number of PCR based studies have isolated
various HPV genotypes from oesophageal tissues [6,37-
39], however the epidemiological evidence of an associa-
tion with HPV-16 has been unclear. In this study we
found a significant association between increased anti
HPV-16 seropositivity and cancer of the oesophagus.
By contrast, no association in relation to anti-HPV-16 IgG
antibodies was observed for prostate cancer. The literature
regarding the association with HPV and the prostate (or a
co-related infection) has been inconclusive. For example
Dillner et al[10] found an increased risk of prostate cancer
in relation to HPV-16 and HPV18 but no association for
HPV-33 and HPV-11. In a subsequent study by Lagergren
et al [7] no such association was found between HPV 16
and 18, but a possible association was found for HPV-33.
Conclusion
If there is indeed an association between HPV-16 and
oesophageal and possibly also some oral cavity and pha-
ryngeal cancers, then emerging HPV vaccines may alsoInfectious Agents and Cancer 2007, 2:6 http://www.infectagentscancer.com/content/2/1/6
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reduce, at least in part, the incidence of these leading can-
cer types.
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